UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39727 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 8 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39727 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware ...

Revenue and Bookings - Revenue increased by $10.6 million, or 17.7%, to $70.1 million for the year ended December 31, 2022, compared to $59.6 million in 2021, primarily driven by higher opening backlog[236] - Backlog as of December 31, 2022, was $172.9 million, an increase of $9.1 million, or 5.5%, from $163.9 million in 2021[225] - Net bookings decreased by $84.7 million, or 51.7%, to $79.2 million for the year ended December 31, 2022, compared to $163.9 million in 2021, primarily due to elongated sales cycles and COVID-related cancellations[225] - The company’s revenue primarily comes from enabling clinical trials through technology and services, and licensing its proprietary technology platform[307] Expenses and Losses - Cost of revenue increased by $11.9 million, or 28.0%, to $54.3 million for the year ended December 31, 2022, compared to $42.4 million in 2021, mainly due to increased compensation-related expenses and consulting fees[237] - Selling, general and administrative expenses rose by $30.1 million, or 41.2%, to $103.3 million for the year ended December 31, 2022, compared to $73.1 million in 2021, representing 147.2% of revenue[238] - Loss from operations for the year ended December 31, 2022, was $152.0 million, compared to a loss of $63.7 million in 2021[235] - Total operating expenses increased to $222.2 million for the year ended December 31, 2022, from $123.3 million in 2021[235] - The net loss for 2022 was $50,988,000, compared to a net loss of $94,331,000 in 2021, indicating an improvement of 46%[285] - The company reported a basic and diluted net loss per share of $0.44 for 2022, compared to $2.89 for 2021[285] Cash Flow and Financial Position - As of December 31, 2022, the company had cash and cash equivalents of $108.1 million and recorded a net loss of $51.0 million for the year[244] - Net cash used in operating activities for the year ended December 31, 2022 was $75.4 million, compared to $36.5 million for the year ended December 31, 2021[249] - Net cash used in investing activities for the year ended December 31, 2022 was $31.9 million, consisting of $31.7 million in capitalized software development costs[252] - Net cash provided by financing activities for the year ended December 31, 2022 was $0.6 million, a significant decrease from $238.2 million in 2021[255] - Cash and cash equivalents decreased to $108,091,000 as of December 31, 2022, down from $214,601,000 in 2021, a decline of 49.6%[283] - The total assets of the company were $126,448,000 as of December 31, 2022, significantly lower than $260,798,000 in 2021, a decrease of 51.5%[283] Technology and Operations - The company operates under one reporting segment, focusing on patient-centric clinical trials and decentralized clinical trial designs[216] - The proprietary technology platform supports the company's unique model, enabling recruitment of patients without traditional site infrastructure costs[215] - The company recognizes revenue based on the transfer of control of services to customers, primarily through service contracts that can last from a few months to several years[310] - The company utilizes a cost-based input method for revenue recognition, measuring progress based on actual costs incurred relative to total expected costs[311] Impairments and Restructuring - Impairment of long-lived assets for the year ended December 31, 2022 was $44.1 million, due to the carrying value of the asset group being greater than the fair value[240] - Restructuring costs for the year ended December 31, 2022 were $2.6 million, related to a plan that included one-time termination benefits for 81 employees, approximately 15% of the workforce[242] - The company recognized a long-lived asset impairment expense of $43.0 million for the year ended December 31, 2022, due to the carrying value of the asset group exceeding its fair value[334] Shareholder and Stock Information - The company raised $233.5 million through a PIPE financing as part of the merger, net of fees and expenses[298] - Total shares outstanding upon consummation of the Business Combination amounted to 114,707,150 shares[370] - The Company incurred total transaction costs of $23.8 million associated with the Merger and PIPE, with $3.1 million included in selling, general and administrative expenses for the year ended December 31, 2021[369] - The company had 116,432,029 shares of common stock issued and outstanding as of December 31, 2022, compared to 114,991,026 shares in 2021[400] Deferred Revenue and Accounts Receivable - Deferred revenue, classified as a contract liability, consists of customer payments received in advance of performance, and is reduced as performance obligations are satisfied[328] - The aggregate amount of transaction price allocated to unsatisfied performance obligations as of December 31, 2022, was $168.0 million, expected to be recognized over remaining contract terms ranging from 0.1 to 8.6 years[371] - The total accounts receivable and unbilled services increased to $11.79 million in 2022 from $10.97 million in 2021, reflecting a year-over-year growth of 7.43%[375] - Deferred revenue as of December 31, 2022, was $8.3 million, up from $7.6 million in 2021, representing an increase of 9.21%[376]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39727 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 8 ...

Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39727 SCIENCE 37 HOLDINGS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR (Exact name of registrant as specified in its charter) Delaware ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ____________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-39727 ____________________________ SCIENCE 37 HOLDINGS, INC. _____________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39727 Science 37 Holdings, Inc. (Exact name of registrant as specified in its charter) | Delaware | | 84-4278203 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39727 LIFESCI ACQUISITION II CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...